Taysha Gene Therapies (TSHA) EBT Margin (2023 - 2025)

Taysha Gene Therapies has disclosed EBT Margin across 3 years of filings, most recently posting 2099.17% for Q4 2025.

• EBT Margin for Q4 2025 came in at 2099.17%, down 119641.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3819.01% (down 268295.0% YoY), and the FY2025 annual result was 1842.49%, down 82700.0% from the prior year.
• EBT Margin came in at 2099.17% for Q4 2025 at Taysha Gene Therapies, down from 1254.33% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 350.02% in Q3 2023 to a low of 2099.17% in Q4 2025.
• The 3-year median for EBT Margin is 902.77% (2024), against an average of 1007.59%.
• Peak annual rise in EBT Margin reached 53398 bps in 2025, while the deepest fall reached 119641 bps in 2025.
• Taysha Gene Therapies' EBT Margin stood at 417.26% in 2023, then slumped by 116 bps to 902.77% in 2024, then plunged by 133 bps to 2099.17% in 2025.
• The last three EBT Margin figures came in at 2099.17% (Q4 2025), 1254.33% (Q2 2025), and 873.76% (Q1 2025), per Business Quant data.